Key result
Polypharmacy with prophylactic anticoagulation is linked to an ~85% longer hospital stay in burn patients.
Why the study?
The study was conducted to evaluate the safety of anticoagulant use for the prevention of venous thromboembolic complications in burn department patients in the setting of polypharmacy.
Does polypharmacy (>3 drugs) worsen safety laboratory parameters and increase length of stay in burn patients receiving prophylactic anticoagulants compared to those receiving <3 drugs?
Observational (n=100)
No
Does polypharmacy (>3 drugs) worsen safety laboratory parameters and increase length of stay in burn patients receiving prophylactic anticoagulants compared to those receiving <3 drugs?
In burn patients receiving prophylactic anticoagulants, concomitant use of more than 3 drugs is associated with altered liver and coagulation parameters and significantly prolonged hospital stays.
Answers are grounded in this paper and cite their sources.
Alerts clinicians to potential risks with polypharmacy in anticoagulated burn patients; leaves open independent causal effects on labs and stay.
The article is devoted to the problem of safety of anticoagulant use in patients with burn injury against the background of polypharmacy. A retrospective analysis of 100 medical records of inpatients in the burn department who received anticoagulants for the prevention of venous thromboembolic complications (VTEC) was conducted for the period from 2022 to 2023, in order to study the safety of using anticoagulants in burn department patients with polypharmacy. According to the analyzed data, in patients taking anticoagulants in prophylactic doses and receiving more than 3 drugs simultaneously, in addition to changes in some clinical and laboratory parameters and coagulogram parameters (a significant increase in the number of blood leukocytes by 18 % (p ≤ 0.002), alanine aminotransferase (ALT) by 61 % (p ≤ 0.0001), aspartate aminotransferase (AST) by 32 % (p ≤ 0.0001), international normalized ratio (INR) by 11 % (p ≤ 0.02), activated partial thromboplastintime (APTT) by 7 % (p ≤ 0.0001), there is an increase in the length of the patient's hospital stay by 7 days (by 85 %, p ≤ 0.00003), compared with those who received less than 3 drugs.
No takes yet. Share an insight, caveat, or question.
Kadyseva et al. (2025) conducted an observational in Burn injury with indication for VTE prophylaxis (n=100). Polypharmacy (>3 drugs simultaneously) vs. ≤3 drugs simultaneously was evaluated on Length of patient's hospital stay (increase by 7 days (85%), p=≤0.00003). Polypharmacy (>3 simultaneous drugs) in burn patients receiving prophylactic anticoagulants was associated with an 85% increase in hospital stay and significant elevations in liver enzymes and coagulation parameters.
Synapse has enriched 10 related papers. Consider them for comparative context: